FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphoma

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for previously treated patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system. The drug received a breakthrough therapy designation for this use.
Source: Food and Drug Administration - Category: American Health Source Type: news

Related Links:

Publication date: Available online 15 July 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Emad I. Wafa, Sean M. Geary, Kathleen A. Ross, Jonathan T. Goodman, Balaji Narasimhan, Aliasger K. SalemAbstractThe primary objective of this study was to enhance the antitumor efficacy of a model cancer vaccine through co-delivery of pentaerythritol lipid A (PELA), an immunological adjuvant, and a model tumor antigen, ovalbumin (OVA), separately loaded into polyanhydride particles (PA). In vitro experiments showed that encapsulation of PELA into PA (PA-PELA) significantly enhanced its stimulatory capacity on...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
Publication date: Available online 14 July 2019Source: Biosensors and BioelectronicsAuthor(s): Maxime Lobry, Driss Lahem, Médéric Loyez, Marc Debliquy, Karima Chah, Mariel David, Christophe CaucheteurAbstractSaccharide sensors represent a broad research area in the scope of sensing devices and their involvement in the medical diagnosis field is particularly relevant for cancer detection at early stage. In that context, we present a non-enzymatic optical fiber-based sensor that makes use of plasmon-assisted tilted fiber Bragg gratings (TFBGs) functionalized for D-glucose biosensing through polydopamine (PDA)-i...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
Targeting IL-6 receptor reduces IgM levels and tumor growth in Waldenström macroglobulinemia. Oncotarget. 2019 May 21;10(36):3400-3407 Authors: Han W, Matissek SJ, Jackson DA, Sklavanitis B, Elsawa SF Abstract The tumor microenvironment (TME) plays an important role in cancer cell biology and is implicated in resistance to therapy. In Waldenström macroglobulinemia (WM), a subtype of Non-Hodgkin lymphoma, the TME modulates WM biology by secreting cytokines that promote the malignant phenotype. In previous work, we have shown that TME-IL-6 promotes WM cell growth and IgM secretion in WM. Tocili...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Selinexor (KPT-330) is a selective inhibitor of nuclear export (SINE) which specifically targets XPO1 (Exportin 1)-mediated nuclear export, leading to increased nuclear retention of major tumor suppressor proteins and inducing selective apoptosis in cancer cells. Several phase I and II clinical trials demonstrate evidence of anti-cancer activity of Selinexor in solid tumors (i.e metastatic prostate cancer (PMID: 29487219), advanced refractory bone or soft tissue sarcoma (PMID: 27458288) and non-small cell lung cancer (PMID: 28647672); as well as, hematological malignancies, including non-Hodgkin lymphoma (PMID: 28468797), ...
Source: Blood - Category: Hematology Authors: Tags: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II Source Type: research
Conclusions: Zanubrutinib was shown to be highly active in patients with R/R MCL, as demonstrated by a high rate of CR documented by PET-based imaging. Zanubrutinib was generally well-tolerated, consistent with previous reports of zanubrutinib treatment in patients with various B-cell malignancies.DisclosuresSong: Peking University Cancer Hospital (Beijing Cancer Hospital): Employment. Zhou: Affiliated Cancer Hospital of Zhengzhou University: Employment; Health and Family Planning Commission of Henan Province: Patents &Royalties: Scientific and technological innovative talents "51282" Project leaders; Henan C...
Source: Blood - Category: Hematology Authors: Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Prognostic Markers and Therapies in Mantle Cell Lymphoma and Waldenstrom ' s Macroglobulinemia Source Type: research
Conclusion: The incidence, prevalence and mortality of BNHL appears to be increasing in Korea, and the occurrence of second primary malignancies is high. BNHL remains an important unmet medical need in South Korea.DisclosuresLiu: Janssen Research &Development, LLC: Employment, Equity Ownership. Qiu: Janssen Research &Development, LLC: Employment, Equity Ownership. Rothwell: Janssen Research &Development, LLC: Employment, Equity Ownership.
Source: Blood - Category: Hematology Authors: Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Poster II Source Type: research
The National Institute for Health and Care Excellence (NICE) in the UK has recommended the use of Janssen Pharmaceutical ’s Imbruvica (ibrutinib) on the Cancer Drugs Fund (CDF) to treat adults with a type of   non-Hodgkin lymphoma called Waldenstr ö m ’s m…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
Waldenström macroglobulinemia (WM) is a subtype of lymphoplasmacytic lymphoma (LPL) that features secretion of monoclonal immunoglobulin type M (IgM) in the blood. WM/LPL occurs most commonly in elderly (median, 73 years) white males and is characterized by an indolent course and relatively long survival. Thus, WM/LPL patients may be at risk for development of subsequent cancers. We used data from the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) program to evaluate the risk of subsequent primary cancer in more than 3800 patients diagnosed with WM or LPL during the 20-year period, 1992 - ...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Epidemiology Source Type: research
In this study, patients meeting the following criteria will be eligible for enrollment: histologically confirmed diagnosis of indolent B-cell NHL, with follicular lymphoma (FL) grade 1-2-3a, marginal zone lymphoma (MZL; splenic, nodal, or extra-nodal), small lymphocytic lymphoma (SLL) with absolute lymphocyte count
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Clinical Trials Source Type: research
Idelalisib (ZYDELIG®, GS-1101) is a first-in-class, targeted, highly selective, oral inhibitor of PI3K that reduces proliferation, enhances apoptosis, and inhibits homing and retention of malignant B cells in lymphoid tissues (Lannutti et al, 2011). We studied idelalisib in 2 registrational trials, one in relapsed chronic lymphocytic leukemia (CLL) and one in refractory, indolent non-Hodgkin lymphoma (iNHL). In the Phase 3 CLL trial (Furman 2014), patients with relapsed disease and multiple co-morbidities precluding the use of chemotherapy were randomized to receive blinded idelalisib 150 mg BID plus rituximab intraven...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: The PI3K-mTOR Network in Hematopoetic Cancers: Oral Presentations - Invited Abstracts Source Type: research
More News: American Health | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Lymphoma | Macroglobulinemia | Non-Hodgkin's Lymphoma | Waldenstrom's Macroglobulinemia